As new genetic markers come to light, whole genome reanalysis can support doctors by analyzing the raw data on drug effectiveness and potential disease indications.
Marco Schito, PhD
Advertisement
Marco Schito, PhD, is scientific and business development director at UGenome AI, a biotechnology company focusing on developing genomics and bioinformatics software for personalized medicine with both research and clinical applications.
Articles by Marco Schito, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Medical Economics
1
DOJ sues Louisiana hospital operator over unnecessary care, referral practices; heart disease, stroke drive more than one-quarter of U.S. deaths; red light therapy vs. CTE – Morning Medical Update
2
Health care lessons from Texas: Effects of losing marketplace subsidies
3
What happens to primary care physicians when patients don’t have health insurance?
4
The physician’s guide to surviving the digital battlefield
5